
BRIEFING

Losartan Potassium. A USP Pending Standard for an amorphous form of Losartan Potassium has been posted on the USP Pending Standards Web page for public comment. No comments were received, and the Monograph Development—Cardiovascular Expert Committee approved the draft as an Authorized USP Pending Standard. Currently, there is an official *USP–NF* monograph for this drug substance, which differs from the polymorphic form in the Pending Standard, with respect to the *Identification* test procedure using infrared spectroscopy and the test for *Water* content. These two tests, *Identification* and *Water*, will be adopted into the *USP–NF*, once the product is fully approved by the FDA, via a flexible monograph approach. The amorphous material is a white to off-white powder, and is freely soluble in water and in methanol.

(MD-CV: S. Ramakrishna) RTS—C61272

Losartan Potassium

v. 1 Authorized September 1, 2008

Add the following:

► **Identification—**

Infrared Absorption (197K).

Water, Method I (921): not more than 5.0%. ◀(1-Sep-2008)